Atanas Ignatov1, Holm Eggemann2, Elke Burger3, Tanja Ignatov2. 1. Department of Obstetrics and Gynecology, Otto-von-Guericke University, G.-Hauptmann Str. 35, 39108, Magdeburg, Germany. atanas.ignatov@gmail.com. 2. Department of Obstetrics and Gynecology, Otto-von-Guericke University, G.-Hauptmann Str. 35, 39108, Magdeburg, Germany. 3. Institute of Biometry and Medical Informatics, Otto-von-Guericke University, Magdeburg, Germany.
Abstract
PURPOSE: To evaluate the pattern of recurrence of breast cancer according to its biological subtype in a large cohort of patients treated with therapy representative of current practice. PATIENTS AND METHODS: Patients treated between 2000 and 2016 with known biological subtype were eligible. Data were prospectively collected. Primary endpoint was the subtype-dependent pattern and time of recurrence. Loco-regional and distant site and time of recurrence were assessed. RESULTS: Median follow-up time was 80.8 months. For 12,053 (82.5%) of 14,595 patients with primary non-metastatic invasive breast cancer a subtype classification was possible. The luminal A subtype had the highest 10-year survival followed by luminal B and luminal/HER2. The worst survival demonstrated HER2 enriched and TNBC. HER2 and TNBC had the highest rate of recurrence in the first 5 years, whereas the rate of recurrence for luminal A and luminal B tumors was initially low, but remained continuously even after 10 years of follow-up. Luminal A tumors demonstrated the lowest rate of distant metastases predominantly in bone. So did luminal B tumors. HER2 enriched subtype was characterized with increased rate of loco-regional recurrence and distant metastases in bone, liver and brain. Luminal/HER2 had pattern of relapse similar to HER2 enriched tumors, with exception of loco-regional relapse and brain metastases. TNBC had higher rate of lung, bone and brain metastases as well as loco-regional relapse. CONCLUSION: Breast cancer subtypes are associated with different time and pattern of recurrence and it should be considered during treatment decision.
PURPOSE: To evaluate the pattern of recurrence of breast cancer according to its biological subtype in a large cohort of patients treated with therapy representative of current practice. PATIENTS AND METHODS: Patients treated between 2000 and 2016 with known biological subtype were eligible. Data were prospectively collected. Primary endpoint was the subtype-dependent pattern and time of recurrence. Loco-regional and distant site and time of recurrence were assessed. RESULTS: Median follow-up time was 80.8 months. For 12,053 (82.5%) of 14,595 patients with primary non-metastatic invasive breast cancer a subtype classification was possible. The luminal A subtype had the highest 10-year survival followed by luminal B and luminal/HER2. The worst survival demonstrated HER2 enriched and TNBC. HER2 and TNBC had the highest rate of recurrence in the first 5 years, whereas the rate of recurrence for luminal A and luminal B tumors was initially low, but remained continuously even after 10 years of follow-up. Luminal A tumors demonstrated the lowest rate of distant metastases predominantly in bone. So did luminal B tumors. HER2 enriched subtype was characterized with increased rate of loco-regional recurrence and distant metastases in bone, liver and brain. Luminal/HER2 had pattern of relapse similar to HER2 enriched tumors, with exception of loco-regional relapse and brain metastases. TNBC had higher rate of lung, bone and brain metastases as well as loco-regional relapse. CONCLUSION:Breast cancer subtypes are associated with different time and pattern of recurrence and it should be considered during treatment decision.
Entities:
Keywords:
Breast cancer; Metastasis; Recurrence; Subtype
Authors: Zsolt Gabos; John Thoms; Sunita Ghosh; John Hanson; Jean Deschênes; Siham Sabri; Bassam Abdulkarim Journal: Breast Cancer Res Treat Date: 2010-09-03 Impact factor: 4.872
Authors: Rachel J D Cossetti; Scott K Tyldesley; Caroline H Speers; Yvonne Zheng; Karen A Gelmon Journal: J Clin Oncol Date: 2014-11-24 Impact factor: 44.544
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Nuria Ribelles; Lidia Perez-Villa; Jose Manuel Jerez; Bella Pajares; Luis Vicioso; Begoña Jimenez; Vanessa de Luque; Leonardo Franco; Elena Gallego; Antonia Marquez; Martina Alvarez; Alfonso Sanchez-Muñoz; Luis Perez-Rivas; Emilio Alba Journal: Breast Cancer Res Date: 2013 Impact factor: 6.466
Authors: Donald Courtney; Matthew G Davey; Brian M Moloney; Michael K Barry; Karl Sweeney; Ray P McLaughlin; Carmel M Malone; Aoife J Lowery; Michael J Kerin Journal: Ir J Med Sci Date: 2022-01-25 Impact factor: 1.568
Authors: Keith L Knutson; Matthew S Block; Nadine Norton; Courtney L Erskine; Timothy J Hobday; Allan B Dietz; Douglas Padley; Michael P Gustafson; Danell Puglisi-Knutson; Toni Kay Mangskau; Saranya Chumsri; Amylou C Dueck; Lavakumar Karyampudi; Glynn Wilson; Amy C Degnim Journal: Clin Cancer Res Date: 2019-11-22 Impact factor: 12.531
Authors: Linda Aagaard Rasmussen; Henry Jensen; Line Flytkjær Virgilsen; Alina Zalounina Falborg; Henrik Møller; Peter Vedsted Journal: BMC Health Serv Res Date: 2019-12-05 Impact factor: 2.655
Authors: Petr Lapcik; Anna Pospisilova; Lucia Janacova; Peter Grell; Pavel Fabian; Pavel Bouchal Journal: Cancers (Basel) Date: 2020-09-16 Impact factor: 6.639